578
Views
0
CrossRef citations to date
0
Altmetric
Meta-opinion

Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden

, , , , , & ORCID Icon show all
Pages 133-138 | Received 20 Dec 2023, Accepted 27 Feb 2024, Published online: 05 Mar 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.